Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 632

1.

CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.

Wang CY, Chao TT, Chang FY, Chen YL, Tsai YT, Lin HI, Huang YC, Shiau CW, Yu CJ, Chen KF.

Lung Cancer. 2014 Aug;85(2):152-60. doi: 10.1016/j.lungcan.2014.05.024. Epub 2014 Jun 5.

PMID:
24954871
2.

TD-19, an erlotinib derivative, induces epidermal growth factor receptor wild-type nonsmall-cell lung cancer apoptosis through CIP2A-mediated pathway.

Chao TT, Wang CY, Lai CC, Chen YL, Tsai YT, Chen PT, Lin HI, Huang YC, Shiau CW, Yu CJ, Chen KF.

J Pharmacol Exp Ther. 2014 Nov;351(2):352-8. doi: 10.1124/jpet.114.215418. Epub 2014 Sep 3.

3.

Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A.

Chao TT, Wang CY, Chen YL, Lai CC, Chang FY, Tsai YT, Chao CH, Shiau CW, Huang YC, Yu CJ, Chen KF.

Oncotarget. 2015 Feb 10;6(4):2164-79.

4.

Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma.

Yu HC, Chen HJ, Chang YL, Liu CY, Shiau CW, Cheng AL, Chen KF.

Biochem Pharmacol. 2013 Feb 1;85(3):356-66. doi: 10.1016/j.bcp.2012.11.009. Epub 2012 Nov 23.

PMID:
23178652
5.

Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer.

Li YY, Lam SK, Mak JC, Zheng CY, Ho JC.

Lung Cancer. 2013 Sep;81(3):354-61. doi: 10.1016/j.lungcan.2013.05.012. Epub 2013 Jun 13.

PMID:
23769318
6.

CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells.

Chen KF, Liu CY, Lin YC, Yu HC, Liu TH, Hou DR, Chen PJ, Cheng AL.

Oncogene. 2010 Nov 25;29(47):6257-66. doi: 10.1038/onc.2010.357. Epub 2010 Aug 23.

PMID:
20729919
7.

Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells.

Liu CY, Hung MH, Wang DS, Chu PY, Su JC, Teng TH, Huang CT, Chao TT, Wang CY, Shiau CW, Tseng LM, Chen KF.

Breast Cancer Res. 2014 Sep 17;16(5):431. doi: 10.1186/s13058-014-0431-9.

8.

Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A.

Yu HC, Hung MH, Chen YL, Chu PY, Wang CY, Chao TT, Liu CY, Shiau CW, Chen KF.

Cell Death Dis. 2014 Jul 31;5:e1359. doi: 10.1038/cddis.2014.325.

9.

[Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].

Han R, Wang X, Zhong D, Zhao J, Chen Z, Sun L, Wang J, Zhang J.

Zhongguo Fei Ai Za Zhi. 2012 Dec;15(12):689-93. doi: 10.3779/j.issn.1009-3419.2012.12.02. Chinese.

10.

Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.

Zou M, Xia S, Zhuang L, Han N, Chu Q, Chao T, Peng P, Chen Y, Gui Q, Yu S.

Int J Oncol. 2013 Jun;42(6):2094-102. doi: 10.3892/ijo.2013.1895. Epub 2013 Apr 12.

PMID:
23588221
12.

Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.

Sano Y, Hashimoto E, Nakatani N, Abe M, Satoh Y, Sakata K, Fujii T, Fujimoto-Ouchi K, Sugimoto M, Nagahashi S, Aoki M, Motegi H, Sasaki E, Yatabe Y.

Mol Cancer Ther. 2015 Feb;14(2):533-41. doi: 10.1158/1535-7163.MCT-14-0456. Epub 2014 Dec 18.

13.

Curcumin lowers erlotinib resistance in non-small cell lung carcinoma cells with mutated EGF receptor.

Li S, Liu Z, Zhu F, Fan X, Wu X, Zhao H, Jiang L.

Oncol Res. 2013;21(3):137-44. doi: 10.3727/096504013X13832473330032.

PMID:
24512728
14.

Roles of MKK1/2-ERK1/2 and phosphoinositide 3-kinase-AKT signaling pathways in erlotinib-induced Rad51 suppression and cytotoxicity in human non-small cell lung cancer cells.

Ko JC, Ciou SC, Jhan JY, Cheng CM, Su YJ, Chuang SM, Lin ST, Chang CC, Lin YW.

Mol Cancer Res. 2009 Aug;7(8):1378-89. doi: 10.1158/1541-7786.MCR-09-0051. Epub 2009 Aug 11.

15.

Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.

Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Barón A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA Jr.

Clin Cancer Res. 2006 Dec 1;12(23):7117-25.

16.

Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells.

Liu CY, Hu MH, Hsu CJ, Huang CT, Wang DS, Tsai WC, Chen YT, Lee CH, Chu PY, Hsu CC, Chen MH, Shiau CW, Tseng LM, Chen KF.

Oncotarget. 2016 Feb 23;7(8):9135-49. doi: 10.18632/oncotarget.7035. Erratum in: Oncotarget. 2017 Feb 7;8(6):10760.

17.

Oridonin inhibits gefitinib-resistant lung cancer cells by suppressing EGFR/ERK/MMP-12 and CIP2A/Akt signaling pathways.

Xiao X, He Z, Cao W, Cai F, Zhang L, Huang Q, Fan C, Duan C, Wang X, Wang J, Liu Y.

Int J Oncol. 2016 Jun;48(6):2608-18. doi: 10.3892/ijo.2016.3488. Epub 2016 Apr 15.

PMID:
27082429
18.

Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer.

Wang M, Zhao J, Zhang LM, Li H, Yu JP, Ren XB, Wang CL.

J Cancer Res Clin Oncol. 2012 Dec;138(12):2069-77. doi: 10.1007/s00432-012-1291-2. Epub 2012 Jul 22.

PMID:
22821179
19.

Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.

Sette G, Salvati V, Mottolese M, Visca P, Gallo E, Fecchi K, Pilozzi E, Duranti E, Policicchio E, Tartaglia M, Milella M, De Maria R, Eramo A.

Cell Death Dis. 2015 Aug 6;6:e1850. doi: 10.1038/cddis.2015.217.

20.

Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model.

Diaz R, Nguewa PA, Parrondo R, Perez-Stable C, Manrique I, Redrado M, Catena R, Collantes M, Peñuelas I, Díaz-González JA, Calvo A.

BMC Cancer. 2010 May 11;10:188. doi: 10.1186/1471-2407-10-188.

Supplemental Content

Support Center